Capecitabine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Capecitabine

Examples of brand names: Xeloda [EU/DE]

ATC code: L01BC06

Main use (for orientation): Oncology

Documented research summary

CBD pilot data concern the CAPOX combination and acute oxaliplatin-associated symptoms. No isolated capecitabine–CBD pharmacokinetics or change in efficacy established.

Uncertainties and limitations

NorthStar oral capecitabine tablets; CAPOX–CBD study concerns the combination and oxaliplatin-associated symptoms, not isolated capecitabine pharmacokinetics.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0227

Type of result: Clinical evidence – limited

Observation: A non-randomised pilot reported fewer acute cold-related symptoms in the CAPOX group.

Mechanism: Adjunctive therapy during CAPOX

Study type: Pilot study

Context studied: CBD 300 mg/day for 8 days, 54 patients across CAPOX/CarboTax groups; oxaliplatin neuropathy endpoints.

Clinical interpretation: Context-specific evidence

Limitations and uncertainties: No isolated capecitabine effect or pair-specific pharmacokinetics; age differences and no randomisation.

Original sources for this finding: Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy. [BMED35933415]

References and access status

[V2_LABEL_D0410] CAPECITABINE (CAPECITABINE) TABLET, FILM COATED [NORTHSTAR RXLLC]

Original source / bibliographic reference

Authors: NorthStar RxLLC

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED35933415] Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy.

Original source / bibliographic reference

Authors: Nielsen SW, Hasselsteen SD, Dominiak HSH, Labudovic D, Reiter L, Dalton SO, Herrstedt J.

Year: 2022

Source type: Publication; title and abstract reviewed

DOI: 10.1007/s00520-022-07312-y

PMID: 35933415

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility